CN101732247A - 一种含有依达拉奉的注射液 - Google Patents
一种含有依达拉奉的注射液 Download PDFInfo
- Publication number
- CN101732247A CN101732247A CN201010022006A CN201010022006A CN101732247A CN 101732247 A CN101732247 A CN 101732247A CN 201010022006 A CN201010022006 A CN 201010022006A CN 201010022006 A CN201010022006 A CN 201010022006A CN 101732247 A CN101732247 A CN 101732247A
- Authority
- CN
- China
- Prior art keywords
- injection
- edaravone
- achromatism
- water
- clarities
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229950009041 edaravone Drugs 0.000 title claims abstract description 65
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 239000007924 injection Substances 0.000 title claims abstract description 53
- 238000002347 injection Methods 0.000 title claims abstract description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000008215 water for injection Substances 0.000 claims abstract description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 32
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 18
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 17
- 238000012546 transfer Methods 0.000 claims description 15
- 230000001186 cumulative effect Effects 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 5
- 206010008118 cerebral infarction Diseases 0.000 abstract description 5
- 230000001154 acute effect Effects 0.000 abstract description 3
- 238000001990 intravenous administration Methods 0.000 abstract description 2
- 239000011780 sodium chloride Substances 0.000 abstract description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 abstract 1
- 239000003978 infusion fluid Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 235000013772 propylene glycol Nutrition 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 28
- 238000012360 testing method Methods 0.000 description 19
- 239000000126 substance Substances 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 239000013558 reference substance Substances 0.000 description 13
- 238000005286 illumination Methods 0.000 description 6
- 239000003708 ampul Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000002932 luster Substances 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 3
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 3
- 241000283977 Oryctolagus Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- -1 Edaravone lipid Chemical class 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010100220060A CN101732247B (zh) | 2010-01-06 | 2010-01-06 | 一种含有依达拉奉的注射液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010100220060A CN101732247B (zh) | 2010-01-06 | 2010-01-06 | 一种含有依达拉奉的注射液 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101732247A true CN101732247A (zh) | 2010-06-16 |
CN101732247B CN101732247B (zh) | 2012-04-25 |
Family
ID=42456621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010100220060A Expired - Fee Related CN101732247B (zh) | 2010-01-06 | 2010-01-06 | 一种含有依达拉奉的注射液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101732247B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101934037A (zh) * | 2010-08-26 | 2011-01-05 | 南京先声东元制药有限公司 | 依达拉奉注射液及其制备工艺 |
CN101933899A (zh) * | 2010-08-26 | 2011-01-05 | 南京先声东元制药有限公司 | 一种依达拉奉注射液及其制备方法 |
CN102335129A (zh) * | 2011-08-03 | 2012-02-01 | 天津市嵩锐医药科技有限公司 | 一种供注射用依达拉奉药物组合物及其制备方法 |
CN103251554A (zh) * | 2013-06-06 | 2013-08-21 | 南京亿华药业有限公司 | 一种稳定的依达拉奉注射液及其制备方法 |
CN104623634A (zh) * | 2015-01-19 | 2015-05-20 | 天津冠勤生物科技有限公司 | 预防、治疗缺血性脑卒中的药物组合物 |
CN105646530A (zh) * | 2014-12-03 | 2016-06-08 | 江苏先声药业有限公司 | 苯基吡唑类化合物及其制备方法与用途 |
CN106668004A (zh) * | 2015-11-06 | 2017-05-17 | 江苏先声药业有限公司 | 依达拉奉和(+)2-莰醇搽剂及其制备方法 |
CN106727287A (zh) * | 2015-11-23 | 2017-05-31 | 江苏先声药业有限公司 | 依达拉奉和天然冰片的高浓度注射液 |
CN110090225A (zh) * | 2019-04-19 | 2019-08-06 | 济南康和医药科技有限公司 | 一种依达拉奉氯化钠注射液及其制备方法 |
CN111840218A (zh) * | 2016-03-16 | 2020-10-30 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7211596B2 (en) * | 2001-05-11 | 2007-05-01 | Mitsubishi Pharma Corporation | Stable high-concentration injection containing pyrazolone derivative |
CN101524352A (zh) * | 2008-03-04 | 2009-09-09 | 江苏先声药物研究有限公司 | 一种含有3-甲基-1-苯基-2-吡唑啉-5-酮的组合物 |
-
2010
- 2010-01-06 CN CN2010100220060A patent/CN101732247B/zh not_active Expired - Fee Related
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101933899A (zh) * | 2010-08-26 | 2011-01-05 | 南京先声东元制药有限公司 | 一种依达拉奉注射液及其制备方法 |
CN101934037B (zh) * | 2010-08-26 | 2013-01-09 | 南京先声东元制药有限公司 | 依达拉奉注射液及其制备工艺 |
CN101934037A (zh) * | 2010-08-26 | 2011-01-05 | 南京先声东元制药有限公司 | 依达拉奉注射液及其制备工艺 |
CN102335129A (zh) * | 2011-08-03 | 2012-02-01 | 天津市嵩锐医药科技有限公司 | 一种供注射用依达拉奉药物组合物及其制备方法 |
CN102335129B (zh) * | 2011-08-03 | 2013-06-05 | 天津市嵩锐医药科技有限公司 | 一种供注射用依达拉奉药物组合物及其制备方法 |
CN103251554A (zh) * | 2013-06-06 | 2013-08-21 | 南京亿华药业有限公司 | 一种稳定的依达拉奉注射液及其制备方法 |
CN105646530B (zh) * | 2014-12-03 | 2020-05-12 | 南京先声东元制药有限公司 | 苯基吡唑类化合物及其制备方法与用途 |
CN105646530A (zh) * | 2014-12-03 | 2016-06-08 | 江苏先声药业有限公司 | 苯基吡唑类化合物及其制备方法与用途 |
CN104623634A (zh) * | 2015-01-19 | 2015-05-20 | 天津冠勤生物科技有限公司 | 预防、治疗缺血性脑卒中的药物组合物 |
CN106668004A (zh) * | 2015-11-06 | 2017-05-17 | 江苏先声药业有限公司 | 依达拉奉和(+)2-莰醇搽剂及其制备方法 |
CN106727287A (zh) * | 2015-11-23 | 2017-05-31 | 江苏先声药业有限公司 | 依达拉奉和天然冰片的高浓度注射液 |
CN106727287B (zh) * | 2015-11-23 | 2020-01-24 | 江苏先声药业有限公司 | 依达拉奉和天然冰片的高浓度注射液 |
CN111840218A (zh) * | 2016-03-16 | 2020-10-30 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
CN110090225A (zh) * | 2019-04-19 | 2019-08-06 | 济南康和医药科技有限公司 | 一种依达拉奉氯化钠注射液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101732247B (zh) | 2012-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101732247A (zh) | 一种含有依达拉奉的注射液 | |
US20240342249A1 (en) | Methods for producing stable therapeutic formulations in aprotic polar solvents | |
WO2009107983A2 (ko) | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 | |
WO2018164513A1 (ko) | 보르테조밉을 포함하는 안정한 제제 및 이의 제조방법 | |
CA2726161C (en) | A peptide derivative and a composition for promoting lacrimal secretion comprising the same | |
US20170035831A1 (en) | Composition comprising bortezomib | |
KR101718733B1 (ko) | 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제 | |
DE69925578T2 (de) | Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten | |
WO2024001964A1 (zh) | 不含乙醇和磷脂的湿热灭菌的尼莫地平组合物及其制备方法 | |
Huang et al. | Combined use of borneol or menthol with labrasol promotes penetration of baicalin through rabbit cornea in vitro. | |
EP4203919B1 (en) | Lipid-based composition for oral administration of bradykinin b2-receptor antagonists | |
CN107106566A (zh) | 晶状体硬化抑制剂 | |
JP3781308B2 (ja) | アルギニンアミド類を含有する医薬製剤 | |
US10668083B2 (en) | Pharmaceutical composition | |
CN108883118B (zh) | 医药组合物 | |
CN101890015B (zh) | 一种哌拉西林钠他唑巴坦钠药物组合物脂质体注射剂 | |
JP2018531905A (ja) | チモシンベータ4を含む眼科用製剤の製造方法 | |
US20180271948A1 (en) | Methods for Producing Stable Therapeutic Glucagon Formulations in Aprotic Polar Solvents | |
KR100509735B1 (ko) | 비페닐디메칠디카르복실레이트 함유 약학적 조성물 | |
CN107998084B (zh) | 一种兰索拉唑冻干粉及其制备方法 | |
WO2017170626A1 (ja) | 水性液剤 | |
WO2024086601A2 (en) | Preserved gip/glp agonist compositions | |
JP2006008696A (ja) | アルギニンアミド類を含有する医薬製剤 | |
KR20130038512A (ko) | 사이클로스포린 함유 안약 조성물 및 그 제조방법 | |
KR20110133889A (ko) | 덱시부프로펜 액상 조성물을 함유하는 밀봉된 경질캡슐제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Changsha Yirui Medical Technology Co., Ltd. Document name: Notification of Decision on Request for Restoration of Right |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 283, Furong house, No. two, Furong section, Yuhua Road, Yuhua District, Hunan, Changsha 410007, China 2305 Patentee after: Changsha Yirui Medical Technology Co., Ltd. Address before: Room 410000, Wanxiang enterprise, Station North Road, Hunan, Changsha, 803 Patentee before: Changsha Yirui Medical Technology Co., Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Changsha Yirui Medical Technology Co., Ltd. Document name: Notification of Passing Examination on Formalities |
|
ASS | Succession or assignment of patent right |
Owner name: HUNAN AIREN MEDICAL INVESTMENT MANAGEMENT CO., LTD Free format text: FORMER OWNER: CHANGSHA YIRUI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20140507 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410007 CHANGSHA, HUNAN PROVINCE TO: 410004 CHANGSHA, HUNAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140507 Address after: 6, 410004 floor, five field logistics park, 97 circuit, Tianxin circuit, Tianxin District, Hunan, Changsha Patentee after: Hunan airen medical Cci Capital Ltd Address before: 283, Furong house, No. two, Furong section, Yuhua Road, Yuhua District, Hunan, Changsha 410007, China 2305 Patentee before: Changsha Yirui Medical Technology Co., Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Hunan airen medical Cci Capital Ltd Document name: Notification to Pay the Fees |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120425 Termination date: 20180106 |
|
CF01 | Termination of patent right due to non-payment of annual fee |